Clinical Trials â WTZ Essen (Westdeutsches Tumorzentrum Essen ...

Clinical Trials – WTZ Essen (Westdeutsches Tumorzentrum Essen) 

Title of Project Indication / Site Phase Sponsor / Funding 

Organization 

Investigator Initiated 

Trial 

Prospective randomized Phase III trial of standard 

definitive boost radiotherapy versus surgery following 

induction chemotherapy with cisplatin/paclitaxel and 

neoadjuvant chemoradiotherapy based on 

hyperfractionated radiotherapy (ESPATü) 

Lung Cancer 

Lung cancer III Universitätsklinikum 

Essen 

Eberhardt, Wilfried, 

Dr. med. 

(IIT) 

A diagnostic companion study to detect circulating tumor 

cells (CTC) harboring somatic epidermal growth factor 

receptor (EGFR) gene mutations in patients with nonsmall 

cell lung cancer (NSCLC) treated with gefitinib, 

erlotinib, cisplatin/pemetrexed or BIBW2992 

EGFR mutant lung 

cancer 

Pilot 

Universitätsklinikum 


Prof. Dr. med. Martin 

Schuler 

(IIT) 

Sorafenib in Resected NSCLC (SIRN) - A Phase II Study 

to Investigate the Efficacy and Safety of Sorafenib as 

Adjuvant Treatment following Resection of Non-small 

Cell Lung Carcinoma (NSCLC) in Patients not eligible for 

Cisplatin-based Adjuvant Chemotherapy 

Thorax II Johannes Gutenberg 

Universität Mainz 


Schuler 

(IIT) 

BI1200.32: Randomized phase III trial of BIBW2992 

versus Cisplatin/Pemetrexed in first-line therapie 

advanced NSCLC haboring EGFR mutations 

BI1200.42: Randomized phase III trial of BIBW2992 in 

combination with paclitaxel versus investigators choice in 

patients with advanced NSCLC relapsing after erlotinib or 

gefitinib 

NSCLC III Boehringer Ingelheim Prof. Dr. med. Martin 

Schuler – Glonal 

NSCLC III Boehringer Ingelheim Prof. Dr. med. Martin 

Schuler – Global 

Coordinating Investigator 

GSK MAGRIT MAGE3-AS15-NSC-003 NSCLC III GlaxoSmithKline no 

RADIANT OSI 774-302 NSCLC III OSI no 

Novartis CRAD001C2114 NSCLC I Novartis no 

SAIL Roche 19390 NSCLC Roche no 

Pfizer A6181087 Erlotinib bs. Erlotinib+SUN NSCLC III Pfizer no

AURORA Nerviano AURA-6202-006 

BERLINStudie Carboplatin + Irinotecan vs Carboplatin + 

Etoposid 

Breast, small cell lung 

and non small cell lung 

cancers. (closed for 

pancreatic, ovarial and 

colorectal cancers) 

II Nerviano no 

SCLC III AIO no 

Bayer 310101 Epothilon-Studie SCLC I / II Schering no 

START EMR 63325-001 NSCLC III Merck no 

TIE ML19747 NSCLC II AIO/Roche no 

TREAT / AIO NSCLC II AIO/Lilly no 

Sanofi Aventis VEGF-Trap VITAL NSCLC II Sanofi Aventis no 

Astra Zeneca REASON NSCLC n/a Astra Zeneca no 

Novartis ATTRACT2 NSCLC III Novartis no 

Pfizer A8081005 NSCLC II Pfizer no 

Pfizer A8081007 NSCLC III Pfizer no 

Roche Humab NO21160 NSCLC Roche no 

Bayer ESCAPE 11961 NSCLC III Bayer no 

Merck EMD72000-031 NSCLC II Merck no 

Pfizer A8501001 NSCLC III Pfizer no 

Bayer PTK NSCLC II Bayer no 

Astra Zeneca D4200C00032 NSCLC III Astra Zeneca no 

Novartis Zometa CZOL446G2419 NSCLC III Novartis no 

Bayer 12006 NEXUS NSCLC III Bayer no 

Astra Zeneca EPICLIN NSCLC n/a Astra Zeneca no 

Celgene AMR PH GL 2007 CL 001 SCLC III Celgene no

Novartis ATTRACT1 NSCLC III Novartis no 

BI1200.23 NSCLC IIb/III Boehringer Ingelheim no 

Stem Cell Transplantation 

Autologous or allogeneic transplantation following 

conventional chemotherapy in younger Patients (18-60 

yrs) with mature ALK negative peripheral T-cell 

lymphoma (DSHNHL 2006-1A) 

Aggressive 

T-cell lymhoma 

Phase III Clinical Trial Center HH Prof.Dr. N. Schmitz 

(coordinating investigator) 

PI Essen: 

Prof. Dr. D. W. Beelen 

AML- SCT 

Allogenic stem cell 

transplantation acute 

myeloic leucemia 

N / A 

Hannover clinical Trial 

Center 

PD Dr. med. Martin Sauer 

Clinical Phase III trial to compare Treosulfan-based 

conditioning therapy with Busulfan-based reducedintensity 

conditioning (RIC) prior to allogeneic stem cell 

transplantation in patients with AML or MDS considered 

ineligible to standard conditioning regimens (MC- 

FludT.14/L)] 

Acute myeloid leukemia 

Myelodysplastic 

syndromes 

Phase III MEDAC GmbH Prof. Dr. D. W. Beelen 


Phase II study Allogeneic Stem Cell Transplantation with 

Treosulfan, VP-16 and Cyclophosphamide for patients 

with Acute Lymphoblastic Leukemia (ALL) not eligible for 

TBI-containing regimens (Allo-SCT -- Treo-VP16-Cyclo / 

ALL) 

Acute lymphoblastic 

leukemia 

Phase II 

CTS 

(Clinical Trial Solutions) 

MEDAC GmbH 

Prof. Dr. D. W. Beelen, 


Prof. Dr. N. Kröger , 

Hamburg 

(coordinating investigators) 

AML: Phase II study of haploidentical hematopoietic cell 

transplantation with CD3/CD19 depleted grafts after a 

reduced intensity conditioning regimen (E 410/2007) 

Acute myeloid leukemia Phase II University Hospital 

Tübingen 

PD Dr. W. Bethge,Tübingen 




Lenalidomide maintenance therapy in patients with MDS 

or AML with cytogenetic abnormalities involving 

monosomy 5 or del5q after allogeneic hematopoietic 

stem cell transplantation - LENAMAINT 

Acute myeloid leukemia 

Myelodysplastic 

syndromes 

Phase I/II ClinAssess Leverkusen PD Dr. U. Platzbecker, 

Dresden 



Prof. Dr. D. W. Beelen

Multicenter randomized study comparing oral 

valganciclovir versus intravenous ganciclovir in patients 

following allogeneic stem cell transplantation (ML 22371) 

Cytomegalovirus 

infection 

Phase III IFE Europe GmbH Prof. Dr. H. Einsele, 

Würzburg 




Evaluation of allogeneic cell transplantation in acute 

myeloid leukemia I (ETAL I) 

Acute myeloid leukemia Phase III DFG Prof. Dr. M. Bornhäuser, 

Dresden 




Prospektive offene multizentrische Phase II-Studie zur 

Effektivität von Palifermin (Kepivance) in der Prophylaxe 

der Mukositis nach allogener Stamzelltransplantation mit 

myeloablativer Ganzkörperbestrahlung (OSHO 76) 

Phase-III study on the value of allogeneic stem cell transplantation 

in poor-risk chronic lymphocytic leukemia 

(GCLLSG/GCTSG CLL-X2 trial) 

Akute und chronische 

Leukämien 

Chronic lymphocytic 

leukemia 

Phase III WISP GmbH PD. Dr. H. Sayer, Jena 




Phase III DFG Prof. Dr. P. Dreger, 

Heidelberg 




Autologous-allogeneic tandem stem cell transplantation 

and maintenance therapy with Thalidomide/DLI for 

patients with multiple myeloma and age ≤ 60 years: a 

phase II-study 

Muliple myeloma Phase II University Medical Center 

Hamburg-Eppendorf 

Prof. Dr. N. Kröger, 

Hamburg 




Double-blind, placebo-controlled, randomized multicenter 

phase III trial to access the efficacy of Sorafenibmaintenance 

therapy in Flt3-ITD positive AML in 

complete remission 

Acute myeloid leukemia Phase II KKS Marburg Prof Dr. A. Neubauer 



Prof. Dr. D. W. Beelen

A randomized, multicenter phase III-study to compare the 

efficacy and safety of early pre-emptive versus minimal 

residual disease (MRD)-triggered administration of 

Imatinib Mesylate (STI571, Glivec) after stem cell 

transplantation for Ph+/BCR-ABL+ acute lymphoblastic 

leukemia (Ph+ALL). 


leukemia 

Phase III Univ. Frankfurt Prof. Dr. O.G. Ottmann, 

Frankfurt 




A randomized, risk and age adapted comparison of the 

dose-dense regimen S-HAM (sequential high-dose 

cytosine arabinoside and mitoxantrone) versus standard 

double induction for initial chemotherapy of adult patients 

with acute myeloid leukemia 

Acute myeloid leukemia Phase III DKH Prof. Dr. W. Hiddemann, 

München 




Multizentrische Therapieoptimierungsstudie der akuten 

lymphatischen Leukaemie bei Erwachsenen und 

Adoleszenten ab 18 Jahren (GMALL 07/2003) - 

Therapieoptimierung durch Evaluation der minimalen 

Resterkrankung - 

Randomisierter kontrollierter Vergleich von Imatinib vs. 

Imatinib und Interferon-alpha vs. Imatinib 800 mg mit 

Prüfung des Stellenwertes der allogenen 

Stammzelltransplantation bei neu diagnostizierter CML in 

chronischer Phase 


leukemia 

Chronische myeloische 

Leukämie 

Phase III DKH Prof. Dr. D. Hoelzer, 

Frankfurt 




Phase IV DKH Prof. Dr. R. Hehlmann, 

Mannheim 




Prospective multicentre validation of National Insitutes of 

Health criteria of chronic graft-versus-host –disease in 

children and adolescents following allogenic stem cell 

transplation 

cGvHD-Project N / A St. Anna-Kinderspital, 

Wien 

Melanoma 

Dr. med. Lawitschka 

Klinische Phase-III Studie der ADO "Individualisierte 

Therapie nach Chemosensitivitätsprofil versus DTIC 

beim metastasierten Melanom" 

Metastasiertes 

Melanom Stadium IIIC 

nicht resezierbar und 

Stadium IV 

III ADO Prof. Dr. Selma Ugurel, 

Uniklinikum Würzburg 

Arbeitsgemeinschaft 

Dermatologische Onkologie 

(ADO)

Adjuvant immunotherapie with anti-CTLA-4 monoclonal 

antibody (ipilimumab) versus placebo after complete 

resection of high-risk Stage III melanoma: A 

Randomized, double-blind Phase 3 trial of the EORTC 

Melanoma Group (BMS CA184 029) 

A double blind, randomized, placebo controlled Phase III 

Study to assess the efficacy of recMAGE-A3+AS15 ASCI 

as adjuvant therapy in Patients with MAGE-A3 positive 

resected stage III melanoma 

An open, single-arm trial to assess the clinical activity of 

recMAGE-A3 + AS15 in Patients with unresectable 

MAGE-A3-positive, metastasic cutaneous melanoma 

ADO-CTCL-3 (TARADO): Multizentrisches Therapie- 

Protokoll zur Bexaroten (Targretin®)-Monotherapie bei 

vorbehandeltem CTCL Stadium ≥Ib mit klarer Zuordnung 

einer EORTC-Diagnose 

PRAME-AS15-MEL-001 (met) An open , dose-escalation 

Phase I/II study to assess the safety, immunogeneticity 

and clinical activity of recPRAME + AS15 Antigen- 

Specific Cancer Immunotherapeutic as first-line 

treatment of patients with PRAME-positive metastati 

Protocol H8K-MC-JZAO A Randomized Phase 3 Study of 

Tasisulam Administered as an Intravenous Infusion on 

Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line 

Treatment in Patients with Metastatic Melanoma 

Malignes Melanom 

Stadium III komplett 

resezierbar 

MAGE-A3-positives 

Melanom Stadium III 

MAGE-A3-positives 

nicht resezierbares 

Melanom Stadium III 

oder IV M1a 

Mycosis fungoides, 

Sezary-Syndrome, 10- 

30 CD30-positive CTCL, 

lymphomatoide 

Papulosen, NK- 

Lymphome 

Phase I: Stadium IV, 

M1b und M1c und 

Patienten mit vollständig 

reseziertem Tumor im 

Stadium IV Phase II: 

Stadium III, messbar 

und nicht resezierbar, 

einschließlich in-transit 

Metastasen und 

Patienten im Stadium 

M1a 

Malignes Melanonom im 

Stadium IV 

III 

Bristol-Myers-Squibb/ 

EORTC 

no 

III Glaxo Smith Kline no 

III Glaxo Smith Kline no 

/ Cephalon Prof. Dr. Reinhard Dummer, 

Universitätsspital Zürich, 

Arbeitsgemeinschaft 

Dermatologische 

Onkologie(ADO) 

I / II Glaxo Smith Kline no 

III Eli - Lilly no

The TEAM Trial (Tasigna Efficacy in advanced 

Melanoma): A randimized, phase III, open-label, multicenter, 

two-arm study to compare the efficacy of Tasigna 

® versus dacarbazine (DTIC) in treatment of Patients 

with inoperable metastatic acral, mucosal or c 

A Randomized, open label, controlled, multicenter, 

Phase III Study in previously untreated Patient with 

unresectable Stage IIIc or Stage IV Melanoma with 

V600-Positive BRAF mutation Receiving RO5185426 or 

Dacarbazine 

SIMPS: An international, prospective, blinded clinical 

study designated to determine the safety and 

effetiveness of the SciBase III device designed to 

distinguish between malignant melanoma and benign 

lesions using electrical impedance spectroscopy 

A randomized, double-blind, vehicle-controlled, 

multicenter 

trial of topically administered LDE225 cream (0.75% bid) 

to 

evaluate clearance of Basal Cell Carcinoma in adult 

patients with Nevoid Basal Cell Carcinoma Syndrome 

Randomisierte Phase III Studie zum Vergleich von 

intravenous versus intraarteriell verabreichtem 

Fotemustin bei Patienten mit Lebermetastasen eines 

Aderhautmelanoms 

NOA-05 phase II trial of procarbazine and lomustine 

chemotherapy (PC) in newly diagnosed gliomatosis 

cerebri 

Therapie für c-Kit- 

Mutation positive 

Patienten des Exon 11 

oder 13, sowie c-Kit 

Mutation Y822D / 

Y823D des Exon 17 bei 

einem metastasierten 

Schleimhautmelanom, 

akralen- oder kutanen 

Melanom 

Für BRAF-positive 

Patienten mit Malignem 

Melanom im nicht 

resezierbaren Stadium 

IIIC oder Stadium IV 

Patienten mit Verdacht 

auf maligne Läsion 

BCC Gorlin Golz 

Syndrom 

III Novartis no 

III Roche no 

MPG SciBase AB no 


Uvealmelanoma III EORTC no 

Neuroectodermal Tumors 

Gliomatosis cerebri / 

Brain 

Multicentric 

phase II study 

N/A 

Prof. Dr. U. Herrlinger, 

Bonn

HIT- HGG 

HIT-REZ 

HIT-HGG - CilMetro 

High Grade 

Glioblastoma 

High Grade Gliomas 

and Refracotry / 

Relapse PNET and 

Medulloblastoma 

refractory High Grade 

Gliomas 

Phase II UK Halle / S. PD Dr. med. Kramm 

Phase II UK Bonn Prof. Dr. med. Fleischhack 

Phase II UK Halle / S PD Dr. med. Kramm 

HIT-REZ. 

intrathecal therapy with 

liposomal cytarabine 

( DepoCyte) 

Phase II 

Mundipharma Research 

UK Bonn 

Prof. Dr. med. Fleischhack 

DIRECTOR – Dose intensified rechallenge with 

temozolomide, one week on one week off versus three 

weeks on one week off in patients with progressive or 

recurrent glioblastoma 

Glioblastoma / Brain 

Multicentric 

phase II study 

Schering-Plough 

Prof. Dr. M. Weller, Zurich 

NOA-08 randomized phase III trial of 1 week on/1 week 

off temozolomide versus involved-field radiotherapy in 

elderly (older than age 65) patients with newly diagnosed 

anaplastic astrocytoma or glioblastoma (Methusalem) 


Multicentric 

phase III study 

Essex Pharma / Schering- 

Plough 

Prof. Dr. W. Wick, 

Heidelberg 

AWB P04739 study on concomitant and adjuvant 

temozolomide and radiotherapy for the treatment of 

glioblastoma 


Multicentric 

post marketing 

survaillance 

study 

N/A 

Prof. Dr. W. Stummer, 

Heidelberg 

Whole Brain radiotherapy (WBRT) vs.WBRT and 

integrated boost using helical tomotherapy for patients 

with multiple brain metastases – a multicentre 

randomized phase II trial 

Brain metastases 

Randomized 

Phase II 

Stuschke 

Other 

Ariad AP23573-07-302 STS II ARIAD no 

EORTC 62931 STS III EORTC no

EORTC 62961 STS III EORTC no 

EORTC 62072 STS III EORTC no 

Sabine STS Surveillance Merck & Co no 

AP23573-07-302 A pivotal trial to determine the efficacy 

and safety of AP23573 when administered as 

maintenance therapiy to patients with metastastic softtissue 

or bone sarcomas 

EORTC 62061: Randomized phase II study of brostallicin 

(PNU-166196A) versus doxorubicin as first line 

chemotherapy in patients with advanced or metastatic 

soft tissue sarcoma 

EORTC 62072: A randomized double blind phase IIIof 

Pazopanib versus placebo in patients with soft tissue 

sarcoma whose disease has progressed during or 

following prior therapy 

STS II ARIAD no 

STS III EORTC no 

STS III EORTC no 

CARIN 

WX/60-006 

CRAD001W2301 (Bolero-3) 

L00070 IN 308 B0 (Vinflunin vs Alkylanz) 

Treatment reality and survival (tumor registry) 

Metastatic breast 

cancer 


cancer 


cancer 


cancer 


cancer 

II, randomis. Iomedico no 

III Wilex AG no 


III Pierre Fabre no 

N/A IOmedico no 

Phase I study of imatinib and LBH589 in imatinib- and 

sunitinib-refractory gastrointestinal stromal tumors 

GIST I Universitätsklinikum 


PD Dr. Sebastian Bauer 

(IIT) 

An open-label, multi-center study to evaluate the efficacy 

of nilotinib in adult patients with gastrointestinal stromal 

tumors resistant to imatinib and Sunitinib 

(CAMN107DDE05) 

GIST II Novartis no

CAMN107G2301 GIST III Novartis no 

S.A.K.K.57-07 GIST II S.A.K.K. no 

CAMN107G2301 A randomized, open-label, multi-center 

phase III study to evaluate the efficacy and safety of 

nilotinib versus imatinib in adult patients with 

unresectable or metastatic gastrointestinal stromal tumor 

GIST) 

GIST III Novartis no 

CAMN107DDE05 GIST III Novartis no 

AMN107A2201: A randomized, open-label, multi-center 

study to evaluate the efficacy of nilotinib versus best 

supportive care with or without a tyrosine kinase inhibitor 

(investigator’s choice) in adult patients with 

gastrointestinal stromal tumors resistant to both imatinib 

and sunitinib 

CRAD001C2454 Everolimus Multicenter, single-arm, 

two-stage phase II trial of RAD001 (everolismus) with 

Glivec in Glivec-resistant patients with progressive GIST 

CAM107A2201 Nilotinib A randomized, open-label, 

multi-center study to evaluate the efficacy of nilotinib 

versus best supportive care with or without a tyrosine 

kinase inhibitor in adult patients with gastrointestinal 

stromal tumors resistant to both imatinib and sunitinib. 

A Phase 3, Randomized, Double-Blind, Placebo- 

Controlled, Multi-Center Study Evaluating the Efficacy 

and Safety of IPI-504 in Patients with Metastatic and/or 

Unresectable Gastrointestinal Stromal Tumors Following 

Failure of at Least Imatinib and Sunitinib 

Merck Expand EMR 20048-052 

Ganymed GM-IMAB-01 


GIST II Novartis no 


GIST III Infinity no 

Advanced Esophago- 

Gastric Cancer 

Advanced 

gastroesophageal 

cancer 

III Merck no 

I Ganymed no 

GC-CIF-2005 met. gastric cancer II AIO no

Sunitinib Sutent SU11248 Gastric cancer II AIO no 

GC-DOR-2004 

Adenocarcinoma, 

gastroesophageal 

transitional 

I / II AIO no 

EORTC 62061 Brostallicin WTS III EORTC no 

Multizentrische Phase II-Studie mit 

Pemetrexed bei Patienten mit vorbehandelten 

metastasierten Weichteilsarkomen 

Randomisierte Phase II-Studie von Trofosfamid versus 

Adriamycin bei älteren Patienten mit unvorbehandeltem 

metastasiertem Weichteilsarkom 

WTS II AIO Prof. Jörg Hartmann, Kiel 

WTS II AIO Prof. Jörg Hartmann, Kiel 

GEN205 

Merck ADVANTAGE 

Lilly H3E-MC-S123 Phase 2 study of pemetrexed in 

combination with cisplatin and cetuximab in recurrent of 

metastatic squamous cell carcinoma of the head and 

neck 

Head and Neck 

carcinoma 

Head and Neck 

carcinoma 

Head and Neck 

carcinoma 

II Genmab no 

II Merck no 

II Lilly no 

Lilly H3E-MC-JMHR 

Head and Neck 

Carcinoma 

III Lilly no 

CeFCiD 

Head and Neck 

carcinoma 

II 

Charite Universitätsklinik 

Berlin 

Prof. Keilholz Charite Berlin 

(IIT) 

DCC 

Head and Neck 

carcinoma 

II 

Charité Universitätsklinik 

Berlin 

Dr. Dr. Raguse Charite 

Berlin (IIT) 

CETAX 

Head and Neck 

carcinoma 

II 

Charité Universitätsklinik 

Berlin 

Prof. Keilholz Charite Berlin 

(IIT) 

Novartis RECORD2 Renal Cell Carcinoma II Novartis no 

GSK COMPARZ Renal Cell Carcinoma III GlaxoSmithKline no

CESAR C-II-006 Renal Cell Carcinoma II CESAR no 

Pfizer AXIS A4061032 RCC III Pfizer no 

Novartis CRAD001L2401 RCC IIIb Novartis no 

Pfizer A6181037 Metastatic RCC II Pfizer no 

Prospektive, randomisierte, kontrollierte, unizentrische, 

offene, Studie zur Thromboembolieprophylaxe mit 

Enoxaparin bei nicht-chirurgischen onkologischen 

Patienten unter systemischer antineoplastischer 

Therapie 

Solide Tumore II Universitätsklinikum 


Prof. Dr. med. M. E. 

Scheulen 

(IIT) 

Astra Zeneca 14-er Solid tumors I Astra Zeneca no 

A phase I, open-label, study of the safety, tolerability and 

pharmacokinetics of pazopanib in combination with 

gemcitabine and gemcitabine plus cisplatin for advanced 

solid tumors 

solid tumors I GlaxoSmithKline no 

A randomized, double-blind, placebo-controlled study 

comparing aflibercept versus placebo on the QTc interval 

in Cancer patients treated with docetaxel. 

solid tumors I Sanofi-Aventis 

Deutschland GmbH 

no 

A Phase I, Open-Label study of the safety, tolerability, 

and pharmacokinetics of Angiocal (PRS-050-PEG40) in 

patients with solid tumor 

Open label, dose escalation trial of oral 4SC-205 in 

patients with advanced malignancies: First-in-man study 

of a newly developed, oral inhibitor of kinesin-spindle 

protein, EG 5 (AEGIS) 

An open phase I single dose escalation study of two 

dosing schedules of BI811283 administered 

intravenously over 24 h continuous infusion in patients 

with advanced solid tumor with repente administration in 

patients with clinical benefit 

A Phase I, open label study evaluating the 

Pharmacokinetics of components of S-1 in patients with 

varying degrees of renal function (S-1111) 

solid tumors I Pieris AG no 

solid tumors I 4SC AG no 

Solid tumors I/IIa Boehringer no 

Solid tumors I Taiho no

A Phase I Dose Escalation study on the tolerability and 

activity of TriN 2755 in patients with advanced solid 

tumors and sarcomas using two different dosage regimes 

Phase II double-blind placebo-controlled trial of CY-503 

in patients with chemotherapy-refractory metastatic 

colorectal cancer 

Solid tumors I TriN no 

Colorectal cancer II CYTAVIS no 

Bayer Correct BAY73-4506 / 14387 Met. CRC III Bayer Health Care no 

Maurice EMR 200020-34 CRC II Merck no 

Merck OPUS EMR 62202-047 CRC II Merck no 

Schering PTK I CRC III Schering No 

Schering PTK II CRC III Schering No 

Petacc8 Colon-Ca III Pierre Fabre no 

Astra Zeneca Horizon-II Met. CRC II Astra Zeneca no 

Celim Met. Hep. CRC II AIO no 

Amgen 20050181 Panitumumab Met. CRC II Amgen no 

Roche Beat Met. CRC n.a. Roche no 

Merck MK-0646 Met. CRC I Merck no 

Velour Met. CRC III Sanofi Aventis no 

Biweekly Cetuximab in combination with FOLFOX-6 as 

first-line treatment in metastatic colorectal cancer 

patients (CEBIFOX) 

Tolerability and efficacy of bevacizumab, capecitabine 

and oxaliplatin as first-line therapy in patients with 

metastatic colorectal cancer (NERO) 

Phase-II-study, radio-chemo-therapy (neoadjuvant) with 

Capecitabine and Oxaliplatin and Bevacizumab for 

patients with advanced rectum-ca (translational research 

project) BEV-XELOX-RT) 

Colorectal cancer II Universitätsklinikum 


Tanja Trarbach, 

Dr. med., MSc 

(IIT) 

Colorectal cancer II Roche Tanja Trarbach, 

Dr. med., MSc 

rectum cancer II Universitätsklinikum 

Schleswig Holstein 

Prof. Dr. med. Dunst. 

Lübeck 

(IIT)

A prospective angiogenic imaging study with DCE-MRI 

and DCE-USI in patients with colorectal cancer and liver 

metastases receiving sunitinib in addition to 5-FU, folic 

acid and irinotecan (FOLFIRI) as 1 st line therapy(C-II- 

005) 

Colorectal Cancer II CESAR Prof. Dr. med. M. E. 

Scheulen 

(IIT) 

AIO KRK 0204 CRC I7II AIO no 

CEBIFOX CRC II Merck, Sanofi Aventis no 

AIO KRK 0504

Two-arm, randomized, open-label, phase IIIb study 

investigating the safety of 2 hour i.p. infusion of 

catumaxomab with and without prednisolone 

premedication in patients with malignant ascites due to 

epithelial cancer 

AMGEN 20050244 

malignant ascites due to 

epithelial cancer 

Bone metastasis, 

advanced Cancer 

(excluding Breast and 

Prostate) or Multiple 

Myeloma 

IIIb Fresenius Biotech GmbH no 

III AMGEN no 

Phase II study to evaluate Glivec (Imatinib Mesylate) to 

induce protression arrest in aggressive fibromatosis / 

desmoids tumors not amenable to surgical resection with 

R0 intent or accompanied by unacceptable function loss 

Desmoid Tumors II IIT Prof. Peter Hohenberger, 

Mannheim 

Saladax 

Bayer REASON 

Valuation of Eligibility of 

5-FU-concentration in 

clinical routine 

Ovarian Cancer/ 

Prostate Cancer 

N/A Saldax Biomedical no 

II Bayer no 

Bingo Advanced biliary cancer II Institut Gustave Roussy, 

France 

no 

SPOT Oesophageal Cancer I/II Sanofi-Aventis no 

Pilot-Study of dose-intensified radiotherapy according to 

PET-CT in combination with induction- and simultaneous 

chemotherapy (SPOT) 

Oesophageal Cancer I/II Universitätsklinikum 



Stuschke (IIT) 

HD-PEI +/- NESF 

met. „poor prognosis“ 

germ cell tumor 

II Amgen no 

Phase I/II study with temsirolimus versus no add-on in 

patients with castration resistant prostate cancer (CRPC) 

receiving first-line Docetaxel chemotherapy (C-II-007) 

Positron-Emissions-Tomographie-gesteuerte Therapie 

aggressiver Lymphome (PETAL) 

Prostate Cancer I/II CESAR Prof. Dr. med. M. E. 

Scheulen 

(IIT) 

Aggressive Lymphome III German Cancer Aid Prof. Dr. U. Dührsen

Valuation of Eligibility of 5-FU-concentration in clinical 

routine (SALADAX) 

Observational Study to explore dermatological side 

effects of patients receiving an Anti-EGFR therapy 

multiple N/A Universitätsklinikum 


Skin N/A Universitätsklinikum 



Dr. med., MSc 

(IIT) 


Dr. med., MSc (IIT) 

Pacet-Cup Unknown Primary II AIO no

Clinical Trials â WTZ Essen (Westdeutsches Tumorzentrum Essen ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

Clinical Trials â WTZ Essen (Westdeutsches Tumorzentrum Essen ...